Agilent snaps up cancer diagnostics firm Biocare for $950M

What's the deal? Agilent TechnologiesDealroom has a profile for this one. Try Dealroom → is acquiring Biocare Medical, a San Francisco Bay Area maker of cancer diagnostics tools, for $950 million in cash. Biocare — sold by private equity firms Excellere PartnersDealroom has a profile for this one. Try Dealroom → and GHO Capital PartnersDealroom has a profile for this one. Try Dealroom → — brings over 300 specialised antibodies and a portfolio of reagents and instruments used in clinical and research pathology.

The deal is expected to close by October 2026. Biocare generated more than $90 million in revenue in 2025.

Why now? Agilent has been actively building out its diagnostics and life sciences capabilities. It bought BiovectraDealroom has a profile for this one. Try Dealroom → for $925 million in 2024 and BioTek InstrumentsDealroom has a profile for this one. Try Dealroom → for $1.17 billion in 2019. Biocare fills a gap in its cancer diagnostics offering, expanding its reach across both clinical labs and research settings.

What could go wrong? Agilent's shares are down 15% in 2026, putting its market cap at $32.5 billion — making a $950 million outlay a meaningful bet. Integration risk is real: folding a specialised, privately held firm into a large public company's diagnostics division can slow the very innovation the deal is meant to accelerate.

The signal: Demand for precision oncology tools is pushing large instrument makers to consolidate niche diagnostics players before they scale independently.

Agilent's string of acquisitions reflects a broader race among life sciences firms to own more of the cancer diagnostics stack — from antibodies and reagents to instruments and software — as pathology workflows become increasingly automated and data-driven.

Sources:
Agilent Technologies Inc.
Business Wire
Reuters
GlobeNewswire
Bloomberg
Investors in Healthcare

J.V.